Live Mycoplasma Gallisepticum Vaccine Research Articles

Immune Response and Histological Changes in Broilers Chickens Vaccinated with Mycoplasma gallisepticum Vaccines.

Mycoplasma is unique among prokaryotes because of its small size, small genomes, and complete lack of cell walls, which makes them cell wall-less prokaryotes. This study aimed to evaluate the effect of vaccinating one-day-old chicks with inactivated and live vaccines (CRDF) of Mycoplasma gallisepticum (MG) on their humoral immune response and immune organs. The Enzyme-Linked Immunosorbent Assay was used to measure Ab titers and investigate histopathological changes. A total of 130 one-day-old broiler chicks were randomly divided into four groups of 30. The groups were treated as follows: G1 included the chicks vaccinated with live F-strain MG vaccine (on eye drop of 0.03ml/dose), G2 included the chicks vaccinated with inactivated MG (0.3 ml s.c) vaccine, G3 included the chicks vaccinated with inactivated and live MG vaccines, and G4 was considered the control group, in which the chicks were not vaccinated. Blood samples were collected on days 21 and 35 of the chick's life to measure the titers of specific antibodies. On day 35, the chicks were dissected, and the bursa of Fabricius, as well as the spleen, were removed for histological evaluations. On day 21, the results showed a significant difference (P≤0.05) between all vaccinated groups in Ab titers, compared to G4, with the highest mean in G3, followed by G2 and G1, in descending order. On day 35, there was a significant difference (P≤0.05) between G3 and other vaccinated groups (G2 and G1), as well as G4. In addition, there was a significant increase in all vaccinated groups on day 35, compared to day 21. In G1, histopathological examination results showed a moderate lymphocytic hyperplasia bursal follicle. In G2, varying degrees of lymphoproliferative were observed in the major bursal follicle, and in G3, a marked lymphocytic hyperplasia bursal follicle was observed. In G4, on the other hand, no obvious histopathological findings were recorded. The results of the spleen histopathological evaluation showed various degrees of lymphoproliferative and moderate neutrophilic infiltrate in the red pulp in G1, and mild sinus congestion with scattered lymphocytes was recorded in the lumen in G2. In the spleen of the chicks in G3, reactive lymphoid hyperplasia was observed. In contrast to the groups mentioned above, in G4, the spleen structure showed a typical structure. It was concluded that the chicks vaccinated with inactivated and live MG vaccines experienced increased production of Ab titers and the immune stimulation of immune organs.

Evaluation of the egg transmission and pathogenicity of Mycoplasma gallisepticum isolates genotyped as ts-11

Live Mycoplasma gallisepticum vaccines are used for the control of respiratory disease, egg production losses and egg transmission associated with M. gallisepticum infection in long-lived poultry. The first field case of apparent increased virulence and vertical transmission of ts-11, a live M. gallisepticum vaccine, has been reported. In that study a M. gallisepticum isolate from the broiler progeny of ts-11-vaccinated breeders was genotyped as ts-11 by sequence analysis of four different genetic targets and Random Amplified Polymorphic DNA and found to be significantly more virulent than ts-11 vaccine. The objective of the current study was to evaluate the rate of egg transmission and pathogenicity of ts-11 vaccine and isolates recovered from ts-11-vaccinated breeders (K6222B) and their broiler progeny (K6216D) which had been genotyped as ts-11. Groups of 28-week-old specific pathogen-free chickens at 87% average weekly egg production were inoculated with sterile broth media (negative controls), ts-11 vaccine, K6222B, K6216D or R strain (positive controls) by eye-drop and aerosol. K6216D transmitted via the egg at an average rate of 4.0% in the third and fourth weeks post-infection, while egg transmission of K6222B and ts-11 vaccine was not detected. M. gallisepticum was isolated from the air sacs, ovaries and oviducts of hens infected with K6216D and K6222B, but not from those infected with ts-11 vaccine. K6216D and K6222B both induced respiratory signs and significantly more tracheal colonization and more severe tracheal and air sac lesions than ts-11 vaccine (P ≤ 0.05). There were no substantial differences in the egg production of ts-11, K6216D and K6222B infected groups. These results provide the first conclusive evidence of transovarian transmission of an isolate genotyped as ts-11 and indicate that isolates genotyed as ts-11 vary in their virulence and ability to transmit via the egg.

The efficacy of Mycoplasma gallisepticum K-strain live vaccine in broiler and layer chickens

The efficacy of a live Mycoplasma gallisepticum (MG) vaccine candidate (K-strain) was compared to commercially available vaccines in broiler-type chickens (Trial 1) and layer-type chickens (Trial 2). In Trial 1, three-week-old broiler-type chickens were vaccinated via aerosol with K-strain or an F-strain vaccine. The vaccinated chickens and 10 non-vaccinated controls were subsequently challenged with virulent R-strain via aerosol at six weeks post vaccination; both K-strain and F-strain vaccination resulted in significant protection from air sac and tracheal lesions, as well as R-strain colonization (P ≤ 0.05). In Trial 2, commercial layer-type chickens were vaccinated with ts-11 (via eye drop) or K-strain (via aerosol) at 12 weeks of age. At 25 weeks of age these birds were challenged with R-strain via aerosol. The ts-11 and K-strain vaccinated groups both had significantly lower air sac lesion scores and a lower prevalence of ovarian regression after challenge as compared to non-vaccinated chickens (P ≤ 0.05). K-strain vaccination also prevented significant tracheal lesions and R-strain colonization (P ≤ 0.05). K-strain shows great potential as a highly efficacious live MG vaccine in broiler and layer-type chickens for protection of the respiratory and reproductive systems as well as prevention of infection with field strains.

Efficacy and Safety of Different Live Mycoplasma gallisepticum Vaccines in Layer Chickens

Efficacy and Safety of Different Live Mycoplasma gallisepticum Vaccines in Layer Chickens

A Comparative Study of Live Attenuated F Strain–Derived Mycoplasma gallisepticum Vaccines

Commercially available attenuated strains of Mycoplasma gallisepticum (MG) are commonly used within the layer industry to control MG-induced mycoplasmosis. Among these are two live MG vaccines derived from the moderately pathogenic MG "chick F" strain. In the present study, the commercially available F strain derivatives were compared for their ability to elicit seroconversion, persist in vivo, and protect against virulent MG-induced airsacculitis. In addition, a noncommercial laboratory-derived high-passage F strain isolate was included in the study. Commercial (Hy-Line W-36) layers were placed in biological isolation units at 9 wk of age (woa). At 10 woa, birds within each biological isolation unit were treated via eye-drop application with one of the three F strain-derived vaccines at one of four levels (1x, 10(-1)x, 10(-2)x, or 10(-3)x). For the commercially available F strain derivatives, 1x equaled the manufacturer's recommended dose. The 1x dose of the noncommercial laboratory-maintained F strain derivative equaled 20 microl of a 48 hr culture. For wk 1-6 postvaccination (p.v.), sera were collected weekly from each bird, and seroconversion was assessed via serum plate agglutination (SPA). Virulent MG (strain R(low)) challenge occurred via intratracheal inoculation at 7 wk p.v. Necropsies were subsequently performed to assess challenge-associated airsacculitus. For each F strain derivative applied at 1x and 10(-1)x, 100% seroconversion, as measured by SPA, was demonstrated by 6 wk p.v., and rates at the 10(-2)x dosage were 10% and 90% for the commercial vaccines and 60% for the laboratory-derived strain in this period. Following challenge, airsacculitis was observed in 66.67% of the nontreated controls but not in any 1x- or 10(-1)x-treated bird independent of applied F strain derivative.

Evaluation of Mycoplasma gallisepticum K-Strain as a Live Vaccine in Chickens

We evaluated the pathogenicity of three live Mycoplasma gallisepticum (MG) vaccine candidates by infection via aerosol of 3-wk-old chickens with log phase broth cultures (trial 1). Two of the candidates (K3020 and K4649A) colonized only 10% and 20% of the chickens, respectively, unlike K2101 (K-strain), which was reisolated from all of the vaccinated chickens tested. K-strain inoculation did not result in significant air sac or tracheal lesions in chickens at 10 and 39 days postinfection (P < or = 0.05). The efficacy of K-strain as a live vaccine was evaluated in trial 2, by challenge of vaccinated chickens with virulent R-strain via aerosol at 6 wk postvaccination. K-strain vaccination resulted in significant protection from air sac and tracheal lesions (P < or = 0.05). The K-strain was further investigated to evaluate transmissibility (trial 3), colonization and persistence of infection following aerosol administration (trial 4), genetic and phenotypic stability following back passage through chickens (trial 5), and vertical transmission (trial 6). The K-strain had a low rate of horizontal transmission; it remained primarily in the respiratory system of inoculated birds and persisted in the upper respiratory tract for the duration of the trial 4 (5 mo). There was no increase in virulence of K-strain when it was back passaged five times through chickens, and no vertical transmission of K-strain was detected. K-strain showed great potential as a safe and effective live MG vaccine.

Characterization of a ts-11–like Mycoplasma gallisepticum Isolate from Commercial Broiler Chickens

Several commercial broiler flocks in northeastern Georgia that were the progeny of the same parent flock (Flock 40) were diagnosed as Mycoplasma gallisepticum (MG) positive by serology, culture, and PCR. Flock 40 had been vaccinated with ts-11 live MG vaccine. Several isolates were obtained from the MG-positive broiler flocks, and these isolates were indistinguishable from the ts-11 vaccine strain by the molecular strain differentiation methods used. A pathogenicity study was performed to compare the virulence of one of the isolates, K6216D, to the ts-11 vaccine strain. K6216D elicited a significantly stronger antibody response and significantly increased colonization of the tracheas and air sacs. K6216D also elicited significantly greater air sac and tracheal lesions than the ts-11 vaccine strain at 10 and 21 days postinoculation (P < or = 0.05). This is the first report of a field case of the apparent reversion to virulence and vertical transmission of the ts-11 vaccine.

Molecular Characterization of Mycoplasma gallisepticum Isolates from Jordan

Two groups of Mycoplasma gallisepticum (MG) isolates (n = 24) from Jordan were analyzed by molecular methods and compared with other Middle Eastern isolates, related international isolates, and reference strains. The first group (n = 19) was isolated from July 2004 to January 2005 (isolation period A), and the newer group (n = 5) from June 2007 to April 2008 (isolation period B). The groups of isolates are from chicken flocks from northern Jordan, but are not from the same farms. None of the flocks were vaccinated for MG. Random amplified polymorphic DNA analysis, targeted sequencing of the partial MG cytadhesin 2 (mgc2), and the MG 16S-23S rRNA intergenic spacer region (IGSR) divided the Jordanian isolates into two groups. All of the 19 isolates from time period A, in addition to two isolates from time period B, were indistinguishable from the F strain. Three of five isolates from time period B were characterized as wild types and were indistinguishable from each other. The wild-type field strain was readily distinguished from the F strain. It was 91% and 96.4% similar to the F strain based on Clustal-W alignments of sequences of mgc2 and IGSR, respectively. Sequence similarity of mgc2 gene of the Jordan wild-type strain to isolates from Israel and Egypt ranged from 96.5% to 100%, whereas for IGSR it was 99.4%-100%. We theorize that the F-strain live MG vaccine, commonly used in Jordan prior to 2007, was transmitted to nonvaccinated poultry in the region and was a predominant genotype during time period A.

Eye Surface Area and Dosage Rates for Spray Vaccination

Spray application of Mycoplasma gallisepticum (MG) vaccines is a labor- and time-saving means of mass vaccination of layer chickens. Recent assessment of spray characteristics of nozzles commonly used to apply MG vaccine in layer chicken operations has shown that the amount of respirable droplets (< 5 microm) is negligible. Topical application of vaccine onto the eye surface has been suggested as a route of vaccination, but no estimates of vaccine load delivered via spray application were found in the literature. Estimates of eye surface area were developed using digital imaging; 24 layer pullets were used for analysis, and the mean eye surface area, corrected for corneal curvature, was found to be 0.609 cm2. This surface area was then used to estimate vaccine load for commercially available live MG vaccine sprayed through popular nozzles. Less than 3000 colony-forming units can be expected for direct deposition onto the surface of an eye.

A Chronicle of Serologic Response in Commercial Layer Chickens to Vaccination with Commercial F Strain Mycoplasma gallisepticum Vaccine

Vaccination of multi-age layer operations, wherein one million plus commercial layer chickens are housed, has been spurious until the development of a self-propelled, constant-speed spray vaccinator. Still, even with its use, live Mycoplasma gallisepticum (MG) vaccinations have been questionable in terms of seroconversion. Using the vaccinator as a research tool over the past 5 yr, factors have been elucidated which impact seroconversion to one live MG vaccine in particular, the F strain of MG (FMG). These factors include the type of nozzle used to spray the vaccine, the temperature of the water used to rehydrate and administer the vaccine, and the pH and osmolarity of the fluid used to apply the vaccine. In the present study, one farm was monitored for its seroconversion rates over 4 1/2 yr, during which time the FMG vaccination protocol was amended as factors were identified that enhanced seroconversion rates. The results of this study showed that implementation and inclusion of the optimized factors into the vaccination protocol for FMG enhanced seroconversion rates because they went from an initial 50%-55% positive seroconversion rate to a consistent 100% positive seroconversion rate over the 56-mo study period.

Effect of Dosage and Vaccination Route on Transmission of a Live Attenuated Mycoplasma gallisepticum Vaccine: A Broiler Model

Mycoplasma gallisepticum (MG) is an economically significant pathogen of poultry species. Among the table egg sector of the poultry industry, live attenuated strains of MG are commonly used to limit production losses associated with MG-induced disease. These vaccines, however, may be problematic to broiler- and turkey-related industries because of associated virulence; therefore, an understanding of the transmissibility of the live MG vaccines is of particular importance. In the present study, a broiler model addresses the effect of vaccine application route and dosage on the transmission of the MG vaccine FVAX-MG to commingled unvaccinated subjects for 7 wk postvaccination. Vaccinations occurred at 2 wk of age via eyedrop or spray application at 1 x (4 x 10(6) colony-forming units [cfu]), 10(-3) x (4 x 10(3) cfu), or 10(-6) x (4 cfu) of the manufacturer's recommended dosage, and subsequent transmission to unvaccinated subjects was measured. The serologic response to MG antigen and the presence of MG DNA indicated FVAX-MG transmission only within the 1 x FVAX-MG eyedrop treatment. Among no other treatment was transmission of FVAX-MG detected. The results of the present study demonstrate that the dosage and vaccination route may have direct implications on subsequent transmission of FVAX-MG.

Stabilization of Live Mycoplasma gallisepticum Vaccines During Vaccination with Second-Generation Spray-Vac Vaccine Stabilizer

ABSTRACT Dilution and application of live Mycoplasma gallisepticum vaccines without the use of vaccine-stabilizing compounds may lead to significant loss of vaccine viability and loss of vaccine efficacy. Vaccine viability may decrease because of osmotic lysis of the mycoplasma as well as the presence of free chlorine or other detrimental chemicals in the water. Second-generation Spray-Vac vaccine stabilizer was developed and shown to maintain live Mycoplasma gallisepticum vaccine viability during exposure to free chlorine while protecting from the other factors that appear to decrease vaccine survival in solution. Increased vaccine survival in solution should lead to increased survival of the vaccine during vaccination. Field trial results demonstrate that second-generation Spray-Vac vaccine stabilizer yields excellent results without the need for distilled water or other vaccine-stabilizing compounds.

Effect of Selected Water Temperatures Used in Mycoplasma gallisepticum Vaccine Reconstitution on Titer at Selected Time Intervals

Numerous methods are currently used throughout the poultry industry for the administration of vaccines. Each utilizes water for vaccine reconstitution and/or administration, including two of the three commercially available live Mycoplasma gallisepticum (MG) vaccines. Selected water temperatures were used to reconstitute and/or dilute the three commercially available live MG vaccines. Water temperatures included 4 C, 22 C (room temperature), and 32 C, and titer (color change units) was recorded at four time intervals, at point of reconstitution (time 0), 15, 30, and 60 min postreconstitution of the vaccines (time periods 15, 30, and 60, respectively). Results for F strain MG (FMG) vaccine showed significant decreases in titer from time 0 to time 15 for the 22 C and 32 C water temperatures but no significant decrease for any time period for FMG reconstituted with 4 C water. For 6/85 strain MG no significant difference in titer was noted for any of four time periods within any of the three water temperatures. For ts-11 strain MG a significant decrease was observed in titer at each of the four postdilution time periods when diluted with 32 C water. There was no significant decrease in titer at any time period for ts-11 MG vaccine when diluted with either 4 C or 22 C water.

The effect of a live vaccine on the horizontal transmission of Mycoplasma gallisepticum

The effect of a live Mycoplasma gallisepticum vaccine on the horizontal transmission of this Mycoplasma species was quantified in an experimental animal transmission model in specific pathogen free White Layers. Two identical trials were performed, each consisting of two experimental groups and one control group. The experimental groups each consisted of 20 birds 21 weeks of age, which were housed following a pair-wise design. One group was vaccinated twice with a commercially available live attenuated M. gallisepticum vaccine, while the other group was not vaccinated. Each pair of the experimental group consisted of a challenged chicken (10(4) colony-forming units intratracheally) and a susceptible in-contact bird. The control group consisted of 10 twice-vaccinated birds housed in pairs and five individually housed non-vaccinated birds. The infection was monitored by serology, culture and quantitative polymerase chain reaction. The vaccine strain and the challenge strain were distinguished by a specific polymerase chain reaction and by random amplified polymorphic DNA analysis. In both experiments, all non-vaccinated challenged chickens and their in-contact 'partners' became infected with M. gallisepticum. In the vaccinated challenged and corresponding in-contact birds, a total of 19 and 13 chickens, respectively, became infected with M. gallisepticum. Analysis of the M. gallisepticum shedding patterns showed a significant effect of vaccination on the shedding levels of the vaccinated in-contact chickens. Moreover, the Cox Proportional Hazard analysis indicated that the rate of M. gallisepticum transmission from challenged to in-contact birds in the vaccinated group was 0.356 times that of the non-vaccinated group. In addition, the overall estimate of R (the average number of secondary cases infected by one typical infectious case) of the vaccinated group (R = 4.3, 95% confidence interval = 1.6 to 49.9) was significantly lower than that of the non-vaccinated group (R = infinity, 95% confidence interval = 9.9 to infinity). However, the overall estimate of R in the vaccinated group still exceeded 1, which indicates that the effect of the vaccination on the horizontal transmission M. gallisepticum is insufficient to stop its spread under these experimental conditions.

Initial Proteomics Analysis of Differentially Expressed Proteins from Mycoplasma gallisepticum Vaccine Strains ts-11 and F Detected by Western Blotting

Mycoplasma gallisepticum (MG) is the causative agent of chronic respiratory disease in laye r chickens. The live MG vaccine strains that are available for use in layer chickens include F, ts-11 and 6/85. The MG vaccine strains ts-11 and 6/85 are safer than F and they have little or no potential of spreading from bird to bird. However, ts-11 and 6/85 appear to be less efficacious than F-strain. Results from studies suggest that the use of MG vaccine strain F in replacement flocks over a period of time results in th e displacement of the original field strain. Also, reports of MG breaks in layer flocks previously vaccinated with ts-11 or 6/85 have resulted in revaccination of these flocks with F. The continued use of F-strain in displacement and revaccination regimens necessitates the development of more rapid and sensitive field tests that will differentiate between wild-type and vaccine strains of MG. In the present study, ts-11 and F- strain whole cell extracts were analyzed by Western blotting and proteomic methodologies. Differentially expressed protein bands were excised, in-gel digested with trypsin, and analyzed by mass spectrometry. The proteins were identified as internal proteins and were predicted to be involved in such cellular processes as carbohydrate transport and metabolism, energy production and conversion, posttranslational modification, protein turnover, chaperone activity, transcription, and translation. The results of this study suggest that proteomics may aid in the characterization of proteins that could contribute to the development and improvement of current MG diagnostic tests.

Serologic response of SPF chickens to live vaccines and other strains of Mycoplasma gallisepticum

False positive serologic reactions and difficulties in the diagnosis of Mycoplasma gallisepticum (MG) in chickens have increased lately as a result of infection by low virulent MG strains and the use of live MG vaccines in poultry. The objective of this study was to evaluate the serologic responses of SPF chickens exposed to the three commercially available live MG vaccines, and one low virulent MG strain (MG-70), contributing to the diagnosis and monitoring of MG infection in birds. Six groups of SPF chickens were used. The control group was not infected nor challenged; one group was infected with the low virulent strain MG-70 (MG-70); three groups were immunized and named after the MG vaccine used, i.e., MG-6/85, MG-ts11, and MG-F; and finally one group was infected with the virulent MG standard strain, MGR. Random Amplification of Polymorphic DNA (RAPDPCR) was used to compare the strains to each other, to the standard MG-A5969, and to MGR. All strains were found to be genetically distinguishable from each other. Birds in the control group showed negative results throughout the experiment and showed no cross-reaction with M. synoviae in any serologic test. ELISA tests at 21 days post first exposure (P1E) and seven days after the second exposure (P2E), evidenced that 25% of the MG70 birds were positive, whereas vaccine groups yielded higher positivity rate, i.e., 57%, 43% and 29% for MG-6/85, MG-ts11 and MG-F, respectively. Serum plate agglutination (SPA) evidenced the first positive results at 35 days P1E on birds in the MG-F group at the rate of 100%; followed by 40% of birds in the MG-70 group at 63 days P1E. Chickens in MG-ts11 and MG 6/85 groups had identical behavior and yielded 100% positive SPA at 77 days P1E. In regard to hemagglutination inhibition (HI), 14 % of the birds in MG-F and MG-ts11 reacted at 42 days P1E, while MG-70 and MG-6/85 groups yielded positive results only after challenge; MG-70 birds reacted at 56 days P1E at the rate of 17% against 63 days P1E for 100% of MG-6/85 birds. The time lag for positive serologic response was monitored on a weekly basis and was statistically different among groups (p<0.05) by Analysis of Variance (ANOVA). No clinical signs or gross lesions were seen in the control, vaccinated or MG-70 infected birds. Tracheitis and airsaculitis were observed in birds in the MG-R group. MG was isolated from all studied groups.

Isolation and characterization of a 6/85-like Mycoplasma gallisepticum from commercial laying hens.

Eighty-three-week-old table egg layers with swollen sinuses were presented with a history of increased mortality. Serology revealed positive titers to Mycoplasma gallisepticum (MG). The birds were part of a flock in which some birds had been vaccinated with 6/85 live MG vaccine at 18 wk of age. Tracheal cultures were obtained from both vaccinated and unvaccinated birds within the flock. The cultures were indistinguishable from 6/85 vaccine by both random amplified polymorphic DNA analysis and DNA sequence analysis. Challenge studies were performed to compare the field isolates with 6/85 vaccine and the R strain of MG. The field isolates produced a greater antibody response by serum plate agglutination than did the 6/85 vaccine. The isolates effectively colonized the trachea without increasing the tracheal mucosal thickness; however, they did not extensively colonize the air sacs or cause airsacculitis in the experimental birds.

A modified live Mycoplasma gallisepticum vaccine to protect chickens from respiratory disease

The aim of this study was to assess the efficacy of a modified live Mycoplasma gallisepticum vaccine (GT5) for the protection of chickens against infection and respiratory disease. GT5 was constructed by the reconstitution of the avirulent high passage R (R high) strain with the gene encoding the major cytadhesin GapA. GT5 expressed GapA on its surface yet retained the phenotypic characteristics of the parental R high strain. Birds vaccinated with GT5 were protected upon challenge with the virulent low passage R (R low) strain as evidenced by a complete absence of tracheal lesions 2 and 4 weeks post-challenge, in contrast to sham immunized/challenged control birds. Modest amounts of IgG, and little, if any secretory IgA or IgM anti- M. gallisepticum were found in tracheal washings following vaccination. However, copious amounts of specific IgA were found following challenge, especially in sham immunized birds. This suggests that the tracheal IgG elicited by GT5 vaccination may have been responsible for blocking the initial colonization of R low, thereby resulting in protection.

The effects of 6/85 live Mycoplasma gallisepticum vaccine in commercial layer hens over a 43-week laying cycle on egg production, selected egg quality parameters, and egg size distribution when challenged before beginning of lay.

In each of two trials, 80 commercial leghorn-type pullets were separated into two treatments with four replicates of 10 chickens in each treatment. Forty pullets were designated as controls and received no inoculation, whereas the remaining 40 pullets received the 6/85 vaccine strain of Mycoplasma gallisepticum (MG) at 10 wk of age. Hen-day egg production, egg weight, eggshell strength, Haugh unit score, pimpling incidence, and blood/meat spot incidence were monitored and recorded weekly in each trial through an entire laying cycle of 43 wk. Further, eggs from all treatments were collected daily, Monday-Thursday, and individually weighed. No significant difference was observed between the treatments for 43-wk means for hen-day egg production, for any of the monitored egg or eggshell quality parameters, or for the number of extra large, large, medium, small, pee wee, or undergrade egg sizes. A significant (P < or = 0.05) difference was observed for the number of jumbo-sized eggs between the two treatments. Results of this study suggest that vaccination of commercial layer chickens at 10 wk of age with 6/85 strain MG does not detrimentally impact egg production, egg size distribution, or ovary/oviduct function as evidenced by selected egg parameters monitored in this study.

Transmissibility of Live Mycoplasma gallisepticum Vaccine Strains ts-11 and 6/85 from Vaccinated Layer Pullets to Sentinel Poultry

In separate trials, layer pullets were vaccinated with Mycoplasma gallisepticum (MG) strain 6/85 or strain ts-11 commercially produced live vaccines. For a 15-wk postvaccination (PV) period, vaccinates were commingled with unvaccinated pullets and were in indirect contact with sentinel groups of pullets, broiler breeders, turkey breeders, or meat turkeys in adjoining pens. Infectivity and transmissibility of vaccine strains were determined by tracheal culture and serology at 1 wk followed by 3-wk intervals PV. Strain 6/85 was recovered from 0%-20% of vaccinates, but not from commingled pullets or sentinel birds. Strain ts-11 was recovered from 60%-90% of vaccinates and 0%-40% of commingled pullets but not from any of the sentinel birds. No birds in the 6/85 vaccine trial tested positive for MG antibodies by serology. MG enzyme-linked immunosorbent assays detected positive responses in ts-11 vaccinates (range = 10%-70%) at 42, 63, 84, and 105 days PV, and commingled pullets (10%) at 84 and 105 days PV. MG serum plate agglutination tests detected positive responses in 90% and 20% of ts-11 vaccinates at 42 and 105 days PV, respectively, and commingled pullets (10%) at day 42 PV. Clinical signs, morbidity, or mortality suggestive of pathogenic MG infection were not observed in any bird during either trial, and no gross lesions were observed at necropsy. Random amplified polymorphic DNA analysis was capable of distinguishing each of the vaccinal strains 6/85 and ts-11 from each other by their distinct DNA banding patterns.